DUXAP9 and urinary bladder carcinoma: Therefore, our findings uncover a molecular mechanism underlying CCL2 overexpression in the cancer cell and suggest that a neutralizing antibody against CCL2 will serve as an effective therapeutic approach for patients with LNMAT1-overexpressing bladder cancers.